Current Report Filing (8-k)
03 June 2023 - 7:04AM
Edgar (US Regulatory)
0001788028
false
0001788028
2023-06-02
2023-06-02
0001788028
JSPR:VotingCommonStockParValue0.0001PerShareMember
2023-06-02
2023-06-02
0001788028
JSPR:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfVotingCommonStockAtExercisePriceOf11.50Member
2023-06-02
2023-06-02
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): June 2, 2023
JASPER THERAPEUTICS, INC.
(Exact
Name of Registrant as Specified in its Charter)
| Delaware |
|
001-39138 |
|
84-2984849 |
(State
or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
2200 Bridge Pkwy Suite #102
Redwood City, California
94065
(Address
of Principal Executive Offices) (Zip Code)
(650)
549-1400
Registrant’s
telephone number, including area code
N/A
(Former
Name, or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Exchange Act:
| (Title
of each class) |
|
(Trading
Symbol) |
|
(Name
of exchange on which registered) |
| Voting Common Stock, par value $0.0001 per share |
|
JSPR |
|
The Nasdaq Stock Market LLC |
| Redeemable Warrants, each whole warrant exercisable for one share of Voting Common Stock at an exercise price of $11.50 |
|
JSPRW |
|
The Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
7.01. Regulation FD Disclosure.
Jasper
Therapeutics, Inc. (the “Company”) is furnishing an updated corporate presentation, attached as Exhibit 99.1 to this
Current Report on Form 8-K (the “Corporate Presentation”), which the Company intends to post on the Company’s website.
The Corporate Presentation is current as of June 2, 2023, and the Company disclaims any obligation to update this material in the
future.
The
information in this Item 7.01, including the Corporate Presentation attached hereto as Exhibit 99.1, is being furnished under Item 7.01
of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by
reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by
specific reference in such a filing.
Item
8.01. Other Events.
The
Corporate Presentation included the following information: the Company recently met with the U.S. Food and Drug Administration (the
“FDA”), which provided the Company with valuable guidance and feedback regarding the Company’s proposed program
for briquilimab for the treatment of Chronic Spontaneous Urticaria (“CSU”).
As a result of the feedback received from the FDA, the Company currently expects to file its investigational new drug application
(“IND”) for briquilimab for the treatment of CSU, and dose the first patient in the study, in the second half of 2023.
The
Company will continue to engage with the FDA towards filing its IND and the launch of the CSU clinical trial.
Forward
Looking Statements
Except
for the factual statements made herein, information contained in this Current Report on Form 8-K consists of forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that are
difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects or future events,
as well as words such as “believes,” “intends,” “expects,” “plans” and similar expressions,
or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking.
Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained
in such statements. For example, there can be no assurance that the Company will meet its expected timing to file the IND with the FDA
or the timing to complete the first patient enrollment for its proposed program for briquilimab for the treatment of CSU, and the outcome
of any anticipated future discussions with the FDA. Reference is also made to other factors detailed from time to time in the Company’s
periodic reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K
and any subsequent Quarterly Reports on Form 10-Q. The forward-looking statements contained in this Current Report on Form 8-K speak
only as of the date of this Current Report on Form 8-K and the Company assumes no obligation to publicly update any forward-looking statements
to reflect changes in information, events or circumstances after the date of this Current Report on Form 8-K, unless required by law.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date: June 2, 2023 |
JASPER THERAPEUTICS, INC. |
| |
|
| |
By: |
/s/ Jeet Mahal |
| |
|
Name: |
Jeet Mahal |
| |
|
Title: |
Chief Operating Officer and
Chief Financial Officer |
2
Amplitude Healthcare Acq... (NASDAQ:AMHCU)
Historical Stock Chart
From May 2024 to Jun 2024
Amplitude Healthcare Acq... (NASDAQ:AMHCU)
Historical Stock Chart
From Jun 2023 to Jun 2024
